Navigation Links
Vanda Pharmaceuticals Reports Third Quarter 2010 Results
Date:11/3/2010

om March of 2010 remains pending.-Net income for the third quarter of 2010 was $3.2 million, compared to net income of $1.3 million for the second quarter of 2010 and a net loss of $7.7 million for the third quarter of 2009.-Basic and diluted net income per common share for the third quarter of 2010 was $0.11, compared to basic and diluted net income per common share of $0.05 and $0.04, respectively, for the second quarter of 2010 and a basic and diluted net loss of $0.28 for the third quarter of 2009.CONFERENCE CALLVanda has scheduled a conference call for today, Wednesday, November 3, 2010, at 10:00 AM ET.  During the call, Mihael H. Polymeropoulos, M.D., President and CEO will discuss quarterly results and other corporate activities.  Investors can call 1-866-730-5768 (domestic) and 1-857-350-1592 (international) prior to the 10:00 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos (participant passcode 11659354).  A replay of the call will be available Wednesday, November 3, 2010 at 1:00 PM ET and will be accessible until Wednesday, November 10, 2010, at 5:00 PM ET.  The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers.  The access number is 14475834.

The conference call will be broadcast simultaneously on Vanda's website, http://www.vandapharma.com.  Investors should click on the Investor Relations tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary software or presentations.  The call will also be archived on Vanda's website for a period of 30 days, through December 3, 2010.

ABOUT VANDA PHARMACEUTICALS INC.:Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders.  For more on Vanda Pharmaceuticals In
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
2. Vanda Pharmaceuticals Reports Third Quarter 2007 Results
3. Vanda Pharmaceuticals Receives FDA Acceptance of Iloperidone New Drug Application
4. Vanda Presents Phase III Iloperidone Efficacy Data
5. Phase III Data Show Vanda Pharmaceuticals Tasimelteon (VEC-162) Significantly Improves Sleep in Patients with Chronic Insomnia
6. Vanda Pharmaceuticals Provides Update on Iloperidone
7. Clinical Trial Results on the Sleep-Promoting Effects of Vanda Pharmaceuticals Circadian Regulator Tasimelteon (VEC-162) Published in The Lancet
8. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
9. Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
10. Vanda Pharmaceuticals Announces Expiration of Hart-Scott -Rodino Waiting Period for Exclusive License of Fanapt(TM)
11. Vanda Pharmaceuticals Announces U.S. Patent Allowance for a Long-Acting Injectable Formulation of Fanapt(TM) (iloperidone) in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... DIEGO, Calif. and RESEARCH TRIANGLE PARK, N.C. ... (Nasdaq: OREX ), a biopharmaceutical company focused on ... a global provider of drug development and manufacturing services, ... Contrave® (naltrexone HCL sustained release (SR)/bupropion HCL SR) as ...
... Inc. (Headquarters: Woodcliff Lake, New Jersey , Chairman and CEO: Hajime Shimizu , "Eisai") today announces ... (Headquarters: Baltimore, Maryland , Director: John Griffin , M.D., "BSI") related to Eisai,s GCPII (glutamate carboxypeptidase ... ... , ...
Cached Medicine Technology:Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R) 2Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R) 3Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R) 4Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R) 5Eisai Enters Licensing Agreement with Johns Hopkins Brain Science Institute 2Eisai Enters Licensing Agreement with Johns Hopkins Brain Science Institute 3
(Date:4/17/2014)... many as 10 million older Americans suffer from depression, ... , However, new research a project that followed ... six years found that Internet use among the ... than 30 percent. , "That,s a very strong effect," ... telecommunication, information studies and media who led the project. ...
(Date:4/17/2014)... affects about one in five infants in the United ... the first several months after birth. Research into probiotic ... however, the April 1, 2014 issue of the ... a study, "Probiotics and Infant Colic," concluding that the ... infant colic did not reduce crying or fussing ...
(Date:4/17/2014)... Medicine (BUSM) have discovered that the anti-seizure drug ... The findings, reported in the American Journal ... to more effective treatments for alcoholism. , Excessive ... causes of illness and death in the U.S. ... the productivity of workers and necessitating huge health ...
(Date:4/17/2014)... by researchers at UC Davis has shown that the ... in cell division, also boosts the mitochondrial activity to ... complex has been shown to perform both jobs. This ... to control cellular energy production, potentially advancing cancer care ... in the journal Developmental Cell . , "These ...
(Date:4/17/2014)... An international research team led by Cesar A. Arias, ... Center at Houston (UTHealth) has identified a new superbug ... The report appeared in the April 17 issue of ... The new superbug is part of a class of ... or MRSA, which is a major cause of hospital ...
Breaking Medicine News(10 mins):Health News:Internet use can help ward off depression among elderly 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2
... , PITTSBURGH, Sept. 22 Precision ... Sean McDonald received the Smart Business Magazine 2009 Pacesetters Award. ... Greater Pittsburgh area who are setting the pace for the ... the impact of their influence in the community-at-large as well ...
... , , , , ... daily syndicated show hosted by cardiac surgeon and health expert Dr. Mehmet Oz, ... clinic at the Reliant Convention Center in Houston, Texas on Saturday September 26, ... of basic health insurance. Dr. Oz will participate in the event and ...
... is too focused on new drug development, while not enough ... in knowledge likely to have the biggest impact on combating ... policy expert says, adding that a major shift in research ... the coming wave of cancer cases. Professor Richard Sullivan ...
... , , RANDOLPH, Mass., Sept. 22 ... to serving individuals with Autism Spectrum Disorders (ASD), today released its ... and adolescents with ASD ever published. , , ... information about the myriad treatments available for ASD," said Susan M. ...
... ... John Conlon, vice president of the company,s Hoosier Region, with one of its two Heartland ... ... America honored John Conlon, vice president of the company,s Hoosier Region, with one of ...
... ... Pediatric Speech Therapy Partnership , ... Atlanta, GA (PRWEB) September 22, 2009 -- Cobb Pediatric Therapy Services, a ... pleased to announce that Travis Consulting, LLC is now operating as its subsidiary, offering ...
Cached Medicine News:Health News:Precision Therapeutics President and CEO Sean McDonald Recipient of 2009 Pacesetters Award 2Health News:'The Dr. Oz Show' and the National Association of Free Clinics Host One Day Free Public Health Clinic at Houston's Reliant Convention Center on September 26 2Health News:'The Dr. Oz Show' and the National Association of Free Clinics Host One Day Free Public Health Clinic at Houston's Reliant Convention Center on September 26 3Health News:'The Dr. Oz Show' and the National Association of Free Clinics Host One Day Free Public Health Clinic at Houston's Reliant Convention Center on September 26 4Health News:'The Dr. Oz Show' and the National Association of Free Clinics Host One Day Free Public Health Clinic at Houston's Reliant Convention Center on September 26 5Health News:Expert calls for new cancer research priorities 2Health News:Expert calls for new cancer research priorities 3Health News:National Autism Center Releases Groundbreaking Report on Autism Treatments 2Health News:National Autism Center Releases Groundbreaking Report on Autism Treatments 3Health News:Conlon Wins Life Care's Heartland Division President's Award 2Health News:Cobb Pediatric Therapy Services Joins Forces with Travis Consulting, LLC to Offer Expanded Services Across the U.S. 2
... Retractor System represents the most widely ... Its wide array of retraction components ... versatile system for multi-directional exposure of ... are available for specific procedures: IMA ...
Rainbow technology combines the latest in system theory, adaptive signal processing and a revolutionary sensor that employs eight wavelengths of light to collect and analyze an extraordinarily rich s...
... real-time PCR analysis of gene expression ... LightCycler 480 System combines amazing speed ... the needs of a broad range ... including array validation, gene-knockdown studies, and ...
... PyGON now offers a very unique product series, ... alarm dialing for refrigerators and freezers. This is ... only a phone line. With our VM500 solution ... to 128 points over one phone line. The ...
Medicine Products: